Register for Correlation shown between Biofield Diagnostic System, Ki-67 Antigen Expression Test
Breast CancerJanuary 26, 2003
2003 JAN 26 - (NewsRx.com & NewsRx.net) -- Biofield Corp. (BZET), developer of the Biofield Diagnostic System (BDS), announced two scientific poster presentations at the 25th International Breast Cancer Symposium in San Antonio, Texas.
Independent studies, conducted by international clinical investigators, showed a direct correlation between the Ki-67 Antigen Expression Test, used to detect breast cancer proliferation through biopsy, and the BDS. Wolfgang Gatzemeier and Alberto Costa (The Maugeri Foundation, Pavia, Italy) presented a prospective study of 103 patients showing statistical significances between BDS and Ki-67 labeling in highly proliferating patient populations. Jack Cuzick (Imperial College Fund, London, England) presented the statistical analysis to validate the correlation.
Virgilio Sacchini (Memorial Sloan-Kettering Cancer Center, New York City) was the lead author on an independent study, which showed the utility of biopotentials measured with the BDS for distinguishing malignant from benign lesions and proliferative from nonproliferative benign lesions. Results of the Post Market Surveillance study, consisting of 389 patients showed a 90% sensitivity and 40% specificity and confirmed the utility of the Biofield test in routine patient management of breast disease.
David M. Long, president and CEO of Biofield, stated that "the research and analysis performed by Drs. Gatzemeier, Costa, Cuzick and Sacchini, and their colleagues, further supports our belief that the BDS is potentially a useful tool in the ongoing worldwide commitment to provide a noninvasive method of accurately diagnosing legions in the breast, while ensuring those patients who may have more aggressive malignancy are triaged to treatment faster." This article was prepared by Medical Devices & Surgical Technology Week editors from staff and other reports.
©Copyright 2003, Medical Devices & Surgical Technology Week via NewsRx.com & NewsRx.net
